[Evaluation of 4-demethoxydaunorubicin toxicity (IMI 30). Preliminary data].
Nobile Mt, R. Rosso(Research Institute for Geo-Hydrological Protection), P. Pronzato(Accademia Nazionale dei Lincei), Lazzaro Repetto, Rita Lionetto, Annalisa Grimaldi(University of Insubria), Elisabetta Campora, Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi)
PubMed
April 25, 1986
Cited by 0
Related Papers
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
|JNCI Journal of the National Cancer Institute|2007|606
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
|Journal of Clinical Oncology|2007|384
Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
|European Journal of Cancer|1996|242